申请人:KUREHA KAGAKU KOGYO KABUSHIKI KAISHA
公开号:EP0654265A1
公开(公告)日:1995-05-24
A pharmaceutical composition comprising a compound of formula (I):
including their stereoisomers and pharmaceutically acceptable salts thereof;
wherein:
each R¹, which may be identical or different if m is greater than 1, is a halogen or phenyl;
m is 0, 1, 2 or 3;
k and n are each independently 0, 1 or 2;
R² and R³ each are independently H or OH;
R⁶ and R⁷ are each independently H or C₁₋₄ alkyl;
R⁸ and R⁹ are each H or R⁸ and R⁹ together form a -C(R⁴)(R⁵)-C(R¹¹)(R¹²)- group, wherein R⁴, R⁵, R¹¹ and R¹² are each independently H or C₁₋₄ alkyl;
Y is N or CH; and
R¹⁰ is H or a halogen, or R¹⁰ together with R² forms an -O- group;
with the proviso that if R⁸ and R⁹ together form a -C(R⁴) (R⁵)-C(R¹¹)(R¹²)- group, R³, R⁶ and R⁷ are each H, and k and n are each 1, then R² and R¹⁰ together form an -O- group; and
a pharmaceutically acceptable carrier or diluent.
一种包含式 (I) 化合物的药物组合物:
包括它们的立体异构体及其药学上可接受的盐;
其中
每个 R¹(如果 m 大于 1,可以相同或不同)是卤素或苯基;
m 是 0、1、2 或 3;
k 和 n 各自独立地为 0、1 或 2;
R² 和 R³ 各自独立地为 H 或 OH;
R⁶ 和 R⁷ 各自独立地为 H 或 C₁₋₄ 烷基;
R⁸和R⁹各自为H或R⁸和R⁹共同形成-C(R⁴)(R⁵)-C(R¹¹)(R¹²)-基团,其中R⁴、R⁵、R¹¹和R¹²各自独立地为H或C₁₋₄ 烷基;
Y 是 N 或 CH;以及
R¹⁰ 是 H 或卤素,或 R¹⁰ 与 R² 一起形成 -O- 基团;
但如果 R⁸ 和 R𠞙 共同形成-C(R⁴) (R⁵)-C(R¹¹)(R¹²)-基团,R³、R⁶ 和 R⁷ 各为 H,且 k 和 n 各为 1,则 R² 和 R¹⁰ 共同形成-O-基团;以及
药学上可接受的载体或稀释剂。